Sinopharm Hyundai (600420.SH) subsidiary ketamine hydrochloride injection obtained drug registration certificate

Zhitong Finance App News, Sinopharm Hyundai (600420.SH) issued an announcement. Recently, Sinopharm Group Industry Co., Ltd. (Sinopharm Industry for short), a wholly-owned subsidiary of the company, received the “Drug Registration Certificate” for ketamine hydrochloride injections approved and issued by the State Drug Administration. Obtaining a registration certificate this time is regarded as passing the consistency evaluation, which will further enrich the company's product range in the anesthesiology and analgesia sector, which is conducive to further enhancing the company's comprehensive market competitiveness in related drug use fields.

According to reports, ketamine (Ketamine) is a classic intravenous anesthetic drug. It was first developed by Parke-Davis in 1962. It has both anesthetic and analgesic effects, and is widely used in the field of anesthesia and severe illness. Ketamine hydrochloride injection was approved and marketed by the US FDA in February 1970. It is an intravenous general anesthetic. It is clinically used as a surgical anesthetic or anesthetic inducer. It is suitable for all kinds of superficial, short surgical anesthesia, diagnostic examination anesthesia, and general complex anesthesia for children. It is a class 1 psychotropic drug.